



Newly Published Article Demonstrates Ultrafiltration with CHF Solutions' Aquadex FlexFlow® System Reduces Hospital Costs by Lowering 90-Day Re-admissions and Durations of Stay in Heart Failure Patients

March 26, 2019

EDEN PRAIRIE, Minn., March 26, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), today announced the publication of "Ultrafiltration vs. Diuretics for Treatment of Fluid Overload in Patients with Heart Failure: A Hospital Cost Analysis" in the *Journal of Medical Economics* showing that the use of ultrafiltration therapy with the company's Aquadex Flex Flow System in heart failure patients reduces hospital readmissions and durations of stay which lowers hospital costs over a 90-day period, compared to diuretic therapy.

"We have for some time highlighted that one of the key advantages to ultrafiltration therapy with the Aquadex system was the cost savings to the hospital and the healthcare system in general," said John Erb, chairman and CEO of CHF Solutions. "It is gratifying to have this claim validated in a peer-reviewed academic journal that covers economic assessments of therapeutics and medical device interventions. We continue to believe that ultrafiltration therapy provides a much needed clinical alternative to diuretic therapy that also provides important economic benefits."

The study examined clinical data from the literature and hospital data from the Healthcare Cost and Utilization Project to follow a decision analytic framework outlining treatment decision, probabilistic outcomes and associated costs for treating heart failure patients with fluid overload (hypervolemia) with either ultrafiltration or diuretic therapy. Results showed that while initial healthcare costs associated with ultrafiltration therapy were higher, fluid removal with ultrafiltration, such as with the Aquadex Flex Flow system, reduced hospital readmissions, leading to a cost savings of \$3,975, or nearly 15 percent, compared to diuretic therapy. The study abstract can be accessed via <https://www.ncbi.nlm.nih.gov/pubmed/30775944>.

About CHF Solutions

CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the benefits of ultrafiltration therapy as compared to diuretic therapy. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

INVESTORS:

Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

-or-

Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com

MEDIA

Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

chf solutions

Source: CHF Solutions, Inc.